In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Ana T López-JiménezDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK. ana.lopez@unige.ch.ORCID 0000-0002-0289-738X Kathryn WrightDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0001-6508-3386 Hannah PainterDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.
Shelby T HoffmeisterDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA.
Lucas JarcheDepartment of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Jeremy BenjaminDepartment of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Gerbrand J van der Heden van NoortDepartment of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0001-5955-6431 Dominik BrokatzkyDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.
Margarida C GomesDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0001-9656-6145 Sydney L MilesDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.
Damián Lobato-MárquezDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0002-0044-7588 Eva-Maria FrickelDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-9515-3442 John RohdeDepartment of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.ORCID 0000-0002-8569-3760 Jonathan N PrunedaDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA.ORCID 0000-0002-0304-4418 Serge MostowyDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK. serge.mostowy@lshtm.ac.uk.ORCID 0000-0002-7286-6503 Funding
Exploiting bacterial effector proteins to study human ubiquitin signalingR35GM142486 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jonathan N Pruneda · 2021 to 2026
$2.6MEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101089193EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 772853 - ENTRAPMENTNIGMS NIH HHS R35 GM142486Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) P2GEP3_188277U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM142486Wellcome TrustWellcome Trust (Wellcome) 206444/Z/17/ZWellcome Trust (Wellcome) 217202/Z/19/ZWellcome Trust (Wellcome) 226644/Z/22/Z
6 · The paper itselfAbstract
Host cells contest invasion by intracellular bacterial pathogens with multiple strategies that recognise and/or damage the bacterial surface. To identify host defence factors targeted to intracellular bacteria, we developed a proximity biotinylation approach coupled to quantitative mass spectrometry that maps the host-bacterial interface during infection. Using this method, we discovered that intracellular Shigella and Salmonella become targeted by UFM1-protein ligase 1 (UFL1), an E3 ligase that catalyses the covalent attachment of Ubiquitin-fold modifier 1 (UFM1) to target substrates in a process called UFMylation. Shigella antagonises UFMylation in a dual manner: first, using its lipopolysaccharide to shield from UFL1 recruitment; second, preventing UFM1 decoration by the bacterial effector IpaH9.8. Absence of UFMylation leads to an increase of bacterial burden in human cells and zebrafish larvae. Contrary to ubiquitylation, the protective role of UFMylation is independent of autophagy. Altogether, our proximity mapping of the host-bacterial interface identifies UFMylation as an ancient antibacterial pathway and holds great promise to reveal other cell-autonomous immunity mechanisms.
Indexed as
Dysentery, BacillaryHost-Pathogen InteractionsProteinsShigella flexneriUbiquitin-Protein LigasesAnimalsAutophagyBacterial ProteinsBiotinylationHeLa CellsHumansLigasesLipopolysaccharidesUbiquitinationZebrafishBacterial ProteinsLigasesLipopolysaccharidesProteinsUbiquitin-Protein LigasesUFM1 protein, human
Identifiers
PMID42897205
PMCPMC13680623
What OpenQuestion holds
Textmetadata
Read underepoch 390